A pivotal Phase 3 trial (APOLLOE4) is ongoing in 325 APOE ε4/ε4 homozygotes with early AD, powered to detect clinically meaningful benefits on cognition and function [81]. This evidence concerns the gene APOE and Alzheimer disease.